Objective To evaluate the clinical effectivity and toxicity of the regimen FMD (fludarabine,
mitoxantrone, dexamethasone) in patients with non-Hodgkin's lymphoma. Methods Thirty …

Methods Twenty-nine patients with lymphoma were enrolled into this study from April 2001
to December 2003. There were 18 male and 11 female patients with median age of 53 years …

Objective To evaluate the therapeutic efficiency and adverse effect of the fludarabine-
containing regimens in the treatment of low grade non-Hodgkin's lymphoma. Methods Thirty …

PURPOSE Fludarabine is an active agent for patients with low-grade lymphoma (LGL) but
has mainly been used as a single agent. This trial was designed to define the maximum …

The purpose of the study was to evaluate response, duration of response, and toxicity of
fludarabine (F), mitoxantrone (M), and dexamethason (D)(FMD) in patients (pts) with …

The treatment results of indolent lymphoid malignancies in Chinese are poorly reported. The
efficacy of FND (fludarabine 25 mg/m< sup> 2/d,× 3; mitoxantrone 10 mg/m< sup> 2/d,× 1; …

Fludarabine Phosphate is an active agent in the treatment of patients with low-grade Non-
Hodgkin's-Lymphoma. This phase II study was initiated to evaluate the antilymphoma activity …

Objective To investigate the efficacy and safety of fludarabine plus mitoxantrone
combination chemotherapy for malignant lymphoma compared with CHOP regimen …

The treatment results of indolent lymphoid malignancies in Chinese are poorly reported. The
efficacy of FND (fludarabine 25 mg/m2/d,× 3; mitoxantrone 10 mg/m2/d,× 1; dexamethasone …

Objective: We performed this prospective, multi-center study to evaluate the efficacy and
safety of fludarabine-based regimes in the treatment of previously untreated and refractory …